Join OurCrowd's VP of Americas Audrey Jacobs for dinner and discussion with global crowdfunding expert Dr. Richard Swart. Also, meet an Israeli medical technology company's CEO Avi Lazar of PulmOne who is raising money through OurCrowd. This event is co-hosted by the Consul and Head of Economic Mission Michal Niddam-Wachsman of the Government of Israel Economic Mission to the US Southern Region and by the Houston Angel Network.
RSVPs are required. Dinner is for accredited investors only. To accredit on our site, click HERE.
Dr. Richard Swart is a PhD in Information Systems, an international award-winning academic and a recognized thought leader in the crowdfunding industry. Richard is a founding member of the Crowdfunding Professional Association (CfPA), the Crowdfunding Intermediary Regulatory Advocates (CIFRA), and an early leader in the field. Richard co-organized the first major national conference on crowdfunding and coordinated several educational events on the JOBS Act throughout the United States. As Director of Research and Analysis for Crowdfund Capital Advisors (CCA) Richard works closely with the University of California, Berkeley in the Innovation in Entrepreneurial and Social Finance Program which is dedicated to academic research on crowdfunding. Richard is currently collaborating on a research project for the World Bank’s InfoDev group exploring crowdfunding and funding models for innovative technology.
Avi Lazar founded PulmOne Advanced Medical Devices Ltd. in March 2006, and has been serving as CEO since its inception. PulmOne developed an innovative diagnostic device, the Minibox, which stands to disrupt the status quo in the area of pulmonary function testing. Prior to PulmOne, Avi served as Chief Executive Officer and Chief Financial Officer in several Israeli technology companies. Avi was instrumental in raising over $50 million from prominent financial and strategic investors and held senior positions with Ernst & Young, where he was responsible for several successful initial public offerings in NASDAQ and TASE. PulmOne’s Minibox innovative device is 1/3 the cost and 1/20 the size of current pulmonary testing centers, offering physicians an enticing alternative. The company received CE (Europe) and FDA (US) approval and has approval to use the same insurance reimbursement code as the current “Gold Standard” Body Box enabling physicians to get a return on their investment in months. PulmOne has a pre-money valuation of $12.5M and OurCrowd and is investing $1.5M of a $3M round alongside leading medical technology venture capital firms.
Since its launch in February of 2013, Israel-based OurCrowd has invested $100 million into 57 companies alongside its 7000 investors from 94 countries. Investors globally are attracted to OurCrowd’s unique equity-crowdfunding platform to identify high quality, vetted and managed Israeli and global startups and invest a minimum of $10K at the same terms as major co-investors.
